{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T03:34:29Z","timestamp":1768016069648,"version":"3.49.0"},"reference-count":25,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T00:00:00Z","timestamp":1692662400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"},{"start":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T00:00:00Z","timestamp":1692662400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100019718","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019718","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019718","name":"Boehringer Ingelheim Espa\u00f1a","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019718","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>In patients hospitalized for acute heart failure (AHF) empagliflozin produced greater clinical benefit than placebo. Many patients with AHF are treated with mineralocorticoid receptor antagonists (MRAs). The interplay between empagliflozin and MRAs in AHF is yet to be explored. This study aimed to evaluate the efficacy and safety of empagliflozin versus placebo according to MRA use at baseline in the EMPULSE trial (NCT04157751).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>In this analysis all comparisons were performed between empagliflozin and placebo, stratified by baseline MRA use. The primary outcome included all-cause death, heart failure events, and a \u22655 point difference in Kansas City Cardiomyopathy Questionnaire (KCCQ) total symptom score at 90\u2009days, assessed using the win ratio (WR). First heart failure hospitalization or cardiovascular death was a secondary outcome. From the 530 patients randomized, 276 (52%) were receiving MRAs at baseline. MRA users were younger, had lower ejection fraction, better renal function, and higher KCCQ scores. The primary outcome showed benefit of empagliflozin irrespective of baseline MRA use (WR\u20091.46, 95% confidence interval [CI] 1.08\u20131.97 and WR\u20091.27, 95% CI 0.93\u20131.73 in MRA users and non-users, respectively; interaction p\u2009=\u20090.52). The effect of empagliflozin on first heart failure hospitalization or cardiovascular death was not modified by MRA use (hazard ratio [HR] 0.58, 95% CI 0.30\u20131.11 and HR 0.85, 95% CI 0.47\u20131.52 in MRA users and non-users, respectively; interaction p\u2009=\u20090.39). Investigator-reported and severe hyperkalaemia events were infrequent (&amp;lt;6%) irrespective of MRA use.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In patients admitted for AHF, initiation of empagliflozin produced clinical benefit and was well tolerated irrespective of background MRA use. These findings support the early use of empagliflozin on top of MRA therapy in patients admitted for AHF.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ejhf.2982","type":"journal-article","created":{"date-parts":[[2023,8,4]],"date-time":"2023-08-04T09:11:59Z","timestamp":1691140319000},"page":"1797-1805","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Mineralocorticoid Receptor Antagonist Use and the Effects of Empagliflozin on Clinical Outcomes in Patients Admitted for Acute Heart Failure: Findings from EMPULSE"],"prefix":"10.1093","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2304-6138","authenticated-orcid":false,"given":"Jo\u00e3o Pedro","family":"Ferreira","sequence":"first","affiliation":[{"name":"Centre d'Investigations Cliniques Plurith\u00e9matique 1433, INSERM, Universit\u00e9 de Lorraine , Nancy ,","place":["France"]},{"name":"F-CRIN INI-CRCT (Cardiovascular and Renal Clinical Trialists), INSERM U1116, Centre Hospitalier R\u00e9gional Universitaire de Nancy , Nancy ,","place":["France"]},{"name":"UnIC@RISE, Cardiovascular Research and Development Center, Department of Surgery and Physiology, Faculty of Medicine of the University of Porto , Porto ,","place":["Portugal"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan P.","family":"Blatchford","sequence":"additional","affiliation":[{"name":"Elderbrook Solutions GmbH, Bietigheim-Bissingen, Germany on behalf of Boehringer Ingelheim, Pharma GmbH & Co. KG , Biberach ,","place":["Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John R.","family":"Teerlink","sequence":"additional","affiliation":[{"name":"Section of Cardiology, San Francisco Veterans Affairs Medical Center and School of Medicine, University of California San Francisco , San Francisco, CA ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mikhail N.","family":"Kosiborod","sequence":"additional","affiliation":[{"name":"Saint Luke's Mid America Heart Institute, University of Missouri-Kansas City , Kansas, MO ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christiane E.","family":"Angermann","sequence":"additional","affiliation":[{"name":"Comprehensive Heart Failure Center W\u00fcrzburg, University and University Hospital W\u00fcrzburg, and Department of Medicine 1, University Hospital W\u00fcrzburg , W\u00fcrzburg ,","place":["Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"Biegus","sequence":"additional","affiliation":[{"name":"Institute of Heart Diseases, Wroclaw Medical University , Wroclaw ,","place":["Poland"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sean P.","family":"Collins","sequence":"additional","affiliation":[{"name":"Department of Emergency Medicine, Vanderbilt University Medical Center , Nashville, TN ,","place":["USA"]},{"name":"Geriatric Research and Education Clinical Care, Tennessee Valley Healthcare Facility VA Medical Center , Nashville, TN ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jasper","family":"Tromp","sequence":"additional","affiliation":[{"name":"Saw Swee Hock School of Public Health, National University of Singapore, the National University Health System, Singapore , Singapore ,","place":["Singapore"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael E.","family":"Nassif","sequence":"additional","affiliation":[{"name":"Saint Luke's Mid America Heart Institute and the University of Missouri , Kansas, MO ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitchell A.","family":"Psotka","sequence":"additional","affiliation":[{"name":"Inova Heart and Vascular Institute, Falls Church , Virginia, VA ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Josep","family":"Comin-Colet","sequence":"additional","affiliation":[{"name":"Hospital Universitari de Bellvitge, University of Barcelona, IDIBELL and CIBERCV , Barcelona ,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert J.","family":"Mentz","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute and Division of Cardiology, Duke University Medical Center , Durham, NC ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martina","family":"Brueckmann","sequence":"additional","affiliation":[{"name":"Boehringer Ingelheim International GmbH , Ingelheim am Rhein ,","place":["Germany"]},{"name":"First Department of Medicine, Faculty of Medicine Mannheim, University of Heidelberg , Mannheim ,","place":["Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matias","family":"Nordaby","sequence":"additional","affiliation":[{"name":"Department of Cardiology, University of Groningen, University Medical Center Groningen , Groningen ,","place":["The Netherlands"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Piotr","family":"Ponikowski","sequence":"additional","affiliation":[{"name":"Institute of Heart Diseases, Wroclaw Medical University , Wroclaw ,","place":["Poland"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adriaan A.","family":"Voors","sequence":"additional","affiliation":[{"name":"Department of Cardiology, University of Groningen, University Medical Center Groningen , Groningen ,","place":["The Netherlands"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2023,8,22]]},"reference":[{"key":"2026010913111750200_ejhf2982-bib-0001","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"key":"2026010913111750200_ejhf2982-bib-0002","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1009492","article-title":"Eplerenone in patients with systolic heart failure and mild symptoms","volume":"364","author":"Zannad","year":"2011","journal-title":"N Engl J Med"},{"key":"2026010913111750200_ejhf2982-bib-0003","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","article-title":"Spironolactone for heart failure with preserved ejection fraction","volume":"370","author":"Pitt","year":"2014","journal-title":"N Engl J Med"},{"key":"2026010913111750200_ejhf2982-bib-0004","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1161\/CIRCULATIONAHA.114.013255","article-title":"Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial","volume":"131","author":"Pfeffer","year":"2015","journal-title":"Circulation"},{"key":"2026010913111750200_ejhf2982-bib-0005","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/j.jacc.2021.01.044","article-title":"Interplay of mineralocorticoid receptor antagonists and empagliflozin in heart failure: EMPEROR-Reduced","volume":"77","author":"Ferreira","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"2026010913111750200_ejhf2982-bib-0006","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/j.jacc.2022.01.029","article-title":"Mineralocorticoid receptor antagonists and empagliflozin in patients with heart failure and preserved ejection fraction","volume":"79","author":"Ferreira","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"2026010913111750200_ejhf2982-bib-0007","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.jchf.2020.11.009","article-title":"Dapagliflozin in HFrEF patients treated with mineralocorticoid receptor antagonists: An analysis of DAPA-HF","volume":"9","author":"Shen","year":"2021","journal-title":"JACC Heart Fail"},{"key":"2026010913111750200_ejhf2982-bib-0008","doi-asserted-by":"crossref","first-page":"2984","DOI":"10.1093\/eurheartj\/ehac306","article-title":"Empagliflozin and serum potassium in heart failure: An analysis from EMPEROR-Pooled","volume":"43","author":"Ferreira","year":"2022","journal-title":"Eur Heart J"},{"key":"2026010913111750200_ejhf2982-bib-0009","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/s41591-021-01659-1","article-title":"The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: A multinational randomized trial","volume":"28","author":"Voors","year":"2022","journal-title":"Nat Med"},{"key":"2026010913111750200_ejhf2982-bib-0010","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1002\/ejhf.2137","article-title":"Sodium-glucose co-transporter 2 inhibition in patients hospitalized for acute decompensated heart failure: Rationale for and design of the EMPULSE trial","volume":"23","author":"Tromp","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026010913111750200_ejhf2982-bib-0011","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1016\/S0140-6736(22)02076-1","article-title":"Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): A multinational, open-label, randomised, trial","volume":"400","author":"Mebazaa","year":"2022","journal-title":"Lancet"},{"key":"2026010913111750200_ejhf2982-bib-0012","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.ijcard.2022.12.045","article-title":"Effect of eplerenone on clinical stability of Japanese patients with acute heart failure","volume":"374","author":"Kobayashi","year":"2023","journal-title":"Int J Cardiol"},{"key":"2026010913111750200_ejhf2982-bib-0013","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1093\/ehjcvp\/pvw016","article-title":"Mineralocorticoid receptor antagonists in patients with heart failure: Current experience and future perspectives","volume":"3","author":"Pitt","year":"2017","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2026010913111750200_ejhf2982-bib-0014","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.ijcard.2023.01.088","article-title":"Spironolactone effect on circulating procollagen type I carboxy-terminal propeptide: Pooled analysis of three randomized trials","volume":"377","author":"Ferreira","year":"2023","journal-title":"Int J Cardiol"},{"key":"2026010913111750200_ejhf2982-bib-0015","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.jacbts.2020.02.004","article-title":"Mechanisms of cardiovascular benefits of sodium glucose co-transporter 2 (SGLT2) inhibitors: A state-of-the-art review","volume":"5","author":"Lopaschuk","year":"2020","journal-title":"JACC Basic Transl Sci"},{"key":"2026010913111750200_ejhf2982-bib-0016","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1093\/cvr\/cvaa064","article-title":"Critical examination of mechanisms underlying the reduction in heart failure events with SGLT2 inhibitors: Identification of a molecular link between their actions to stimulate erythrocytosis and to alleviate cellular stress","volume":"117","author":"Packer","year":"2021","journal-title":"Cardiovasc Res"},{"key":"2026010913111750200_ejhf2982-bib-0017","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1002\/ejhf.1713","article-title":"Randomized, double-blind, placebo-controlled, multicentre pilot study on the effects of empagliflozin on clinical outcomes in patients with acute decompensated heart failure (EMPA-RESPONSE-AHF)","volume":"22","author":"Damman","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026010913111750200_ejhf2982-bib-0018","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1093\/eurheartj\/ehac530","article-title":"Impact of empagliflozin on decongestion in acute heart failure: The EMPULSE trial","volume":"44","author":"Biegus","year":"2023","journal-title":"Eur Heart J"},{"key":"2026010913111750200_ejhf2982-bib-0019","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S0140-6736(22)01429-5","article-title":"SGLT-2 inhibitors in patients with heart failure: A comprehensive meta-analysis of five randomised controlled trials","volume":"400","author":"Vaduganathan","year":"2022","journal-title":"Lancet"},{"key":"2026010913111750200_ejhf2982-bib-0020","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1002\/ejhf.2722","article-title":"Dapagliflozin in patients with heart failure with mildly reduced and preserved ejection fraction treated with a mineralocorticoid receptor antagonist or sacubitril\/valsartan","volume":"24","author":"Yang","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"2026010913111750200_ejhf2982-bib-0021","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1016\/j.jacc.2020.04.021","article-title":"Abnormalities of potassium in heart\u2009failure: JACC state-of-the-art review","volume":"75","author":"Ferreira","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2026010913111750200_ejhf2982-bib-0022","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1002\/ejhf.2578","article-title":"Early changes in estimated glomerular filtration rate post-initiation of empagliflozin in EMPEROR-Reduced","volume":"24","author":"Zannad","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"2026010913111750200_ejhf2982-bib-0023","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1161\/CIRCULATIONAHA.121.058910","article-title":"Initial decline (dip) in estimated glomerular filtration rate after initiation of dapagliflozin in patients with heart failure and reduced ejection fraction: Insights from DAPA-HF","volume":"146","author":"Adamson","year":"2022","journal-title":"Circulation"},{"key":"2026010913111750200_ejhf2982-bib-0024","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1007\/s00392-022-02116-w","article-title":"Early and late renal function changes with spironolactone in patients at risk of developing heart failure: Findings from the HOMAGE trial","volume":"112","author":"Ferreira","year":"2023","journal-title":"Clin Res Cardiol"},{"key":"2026010913111750200_ejhf2982-bib-0025","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1002\/ejhf.2635","article-title":"Effects of steroidal mineralocorticoid receptor antagonists on acute and chronic estimated glomerular filtration rate slopes in patients with chronic heart failure","volume":"24","author":"Vaduganathan","year":"2022","journal-title":"Eur J Heart Fail"}],"container-title":["European Journal of Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/25\/10\/1797\/65556376\/eurjhf_25_10_1797.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/25\/10\/1797\/65556376\/eurjhf_25_10_1797.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T18:14:16Z","timestamp":1767982456000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjhf\/article\/25\/10\/1797\/8342868"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,22]]},"references-count":25,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2023,8,22]]},"published-print":{"date-parts":[[2023,10,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ejhf.2982","relation":{},"ISSN":["1388-9842","1879-0844"],"issn-type":[{"value":"1388-9842","type":"print"},{"value":"1879-0844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,10]]},"published":{"date-parts":[[2023,8,22]]},"assertion":[{"value":"2023-03-31","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-07-18","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-08-22","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}